GW Pharmaceuticals Plc (GWPH): Price and Financial Metrics
GWPH Stock Summary
- The ratio of debt to operating expenses for Gw Pharmaceuticals Plc is higher than it is for about just 8.05% of US stocks.
- Over the past twelve months, GWPH has reported earnings growth of 564.43%, putting it ahead of 97.12% of US stocks in our set.
- Revenue growth over the past 12 months for Gw Pharmaceuticals Plc comes in at 69.34%, a number that bests 92.66% of the US stocks we're tracking.
- Stocks that are quantitatively similar to GWPH, based on their financial statements, market capitalization, and price volatility, are PRO, AIRG, VUZI, ICPT, and RKDA.
- Visit GWPH's SEC page to see the company's official filings. To visit the company's web site, go to www.gwpharm.com.
GWPH Stock Price Chart Interactive Chart >
GWPH Price/Volume Stats
| Current price | $215.14 | 52-week high | $217.50 |
| Prev. close | $214.89 | 52-week low | $67.98 |
| Day low | $214.37 | Volume | 342,038 |
| Day high | $215.26 | Avg. volume | 1,151,028 |
| 50-day MA | $164.22 | Dividend yield | N/A |
| 200-day MA | $127.88 | Market Cap | 6.68B |
GW Pharmaceuticals Plc (GWPH) Company Bio
GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. It operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The company was founded in 1998 and is based in Cambridge, the United Kingdom.
Latest GWPH News From Around the Web
Below are the latest news stories about Gw Pharmaceuticals Plc that investors may wish to consider to help them evaluate GWPH as an investment opportunity.
SHAREHOLDER ALERT: WeissLaw LLP Reminds LACQ, GWPH, PRSP, and CMD Shareholders About Its Ongoing InvestigationsIf you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: |
Cannabinoids in Focus after GW Pharmaceuticals Snapped up for €6BThis month’s €6B acquisition of the UK heavyweight GW Pharmaceuticals by Jazz Pharmaceuticals has been hailed as a major validation of the medical cannabinoid industry. |
SHAREHOLDER ALERT: WeissLaw LLP Reminds EGOV, GRNV, LACQ, and GWPH Shareholders About Its Ongoing InvestigationsIf you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: |
INVESTIGATION ALERT: Halper Sadeh LLP Investigates the Following Companies on Behalf of Shareholders - PTVCA, AEGN, CATM, CHNG, GWPH, PS, SNCAHalper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: |
What Investors Need to Know About Jazz Pharmaceuticals' Planned Acquisition of GW PharmaceuticalsIn the first marijuana industry buyout of 2021, Jazz Pharmaceuticals (NASDAQ: JAZZ) agreed to pay a hefty $7.6 billion to acquire GW Pharmaceuticals (NASDAQ: GWPH), a developer of cannabis-based medications. Corinne Cardina: Another deal that was more recently announced just this week, Jazz Pharmaceuticals announced that they were going to be acquiring GW Pharmaceuticals. |
GWPH Price Returns
| 1-mo | 49.32% |
| 3-mo | 57.68% |
| 6-mo | 114.95% |
| 1-year | 111.15% |
| 3-year | 92.33% |
| 5-year | 439.20% |
| YTD | 86.41% |
| 2020 | 10.38% |
| 2019 | 7.36% |
| 2018 | -26.23% |
| 2017 | 18.13% |
| 2016 | 60.93% |
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...